Navigation Links
BioMarin to Present at the Barclays Global Healthcare Conference
Date:3/8/2011

NOVATO, Calif., March 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Barclays Global Healthcare Conference in Miami on Tuesday, March 15, 2011 at 4:15 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Cowen Health Care Conference
2. BioMarin to Present at the Citi Global Healthcare Conference
3. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
4. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
5. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
6. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
7. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
8. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
9. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
10. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
11. BioMarin Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/9/2017)... 2017 ... coming to Washington DC ... Tuesday, September 12 th – Monday, September 18 th .The Brain ... MRI brain scans to the public.Where:  BTF,s Mobile ... 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road ...
(Date:9/7/2017)... Sept. 7, 2017 Caris Life Sciences, ... fulfilling the promise of precision medicine, today announced ... benefits of its molecular profiling approach in guiding ... genomic profiling plus (CGP+) with Caris Molecular Intelligence ... on a molecular level, leading to more therapeutic ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of Team Decades, http://www.teamdecades.com ... a distinct rather than generic impression in the job market if one is looking ... of resumes knows that the first impression they give off is not a good ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... 5000 , the most prestigious ranking of the nation's fastest-growing private companies. The ... economy’s most dynamic segment— its independent small and midsized businesses. Endo-Systems is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... With ... oldest general contractors in the United States, can easily manage all of their ... cloud and on premise platforms simultaneously. “As a construction company,” says Ryan Sinnwell, ...
(Date:9/18/2017)... , ... September 19, 2017 , ... ... Pacific’s protein ingredient market , expected to grow at the fastest CAGR of ... sharing the ‘Global Food Protein Trends & Growth Opportunities in Asia’ – highlighting ...
(Date:9/18/2017)... Laguna Hills, CA (PRWEB) , ... September 18, 2017 , ... ... solutions, is hosting its Fall DocLink Advanced Admin Training in Irvine, CA. ... will provide attendees with the tools that will allow them to manage DocLink more ...
Breaking Medicine News(10 mins):